EGFR and head and neck squamous cell carcinoma: Currently, the only Food and Drug Administration (FDA)-approved targeted therapy for recurrent or metastatic HNSCC patients is cetuximab, a monoclonal antibody that specifically binds and inhibits the epidermal growth factor receptor (EGFR).